Jaap Goudsmit
Fondateur chez Leyden Laboratories B.V.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Mark Feinberg | M | - |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | - |
Johannes J. P. Kastelein | M | 70 |
Academic Medical Center
Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands.
University of Amsterdam
| - |
Gabriella Etmektsoglou | F | - |
New York University
| - |
Richard W. Gray | M | - |
New York University
| - |
Jan H. Lindenbergh | M | 80 |
University of Amsterdam
| - |
Ronald H. P. Brus | M | 61 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
Domenico Valerio | M | 67 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
John Kastelein | M | 70 |
Academic Medical Center
Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands.
University of Amsterdam
| - |
Evan Chesler | M | - |
New York University
| - |
Koenraad Wiedhaup | M | - |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | - |
Robert Goldberg | M | - |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | - |
Labeeb M. Abboud | M | - |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | - |
Hilde Frafjord Johnson | F | - |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | - |
Philip Himberg | M | - |
New York University
| - |
Bernardo Miguel Fort Brescia | M | 73 |
University of Amsterdam
| - |
Robert Holzer | M | - |
New York University
| - |
Luis A. Miranda | M | - |
New York University
| - |
Patrick C. Hanlon | M | - |
New York University
| - |
Frank A. Shih | M | - |
New York University
| - |
Jaap Winter | M | 61 |
University of Amsterdam
| - |
Alan Burns | M | - |
New York University
| - |
Terry Allen Tevis | M | 82 |
New York University
| - |
Theo Gevers | M | - |
University of Amsterdam
| - |
Mark Dybul | M | 60 |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | - |
Pina LoGiudice | M | - |
New York University
| - |
Luis M. Tormenta | M | - |
New York University
| - |
Peter W. Thonis | M | - |
New York University
| - |
Anil Singh | M | - |
New York University
| - |
Melinda Fine | M | - |
New York University
| - |
John C. Gorman | M | 93 |
New York University
| - |
Ed Lombardo | M | - |
New York University
| - |
Claudio Basilico | M | - |
New York University
| - |
Alan Whiteside | M | - |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | - |
Joyce Howard | M | 66 |
New York University
| - |
Andre Fenton | M | - |
New York University
| - |
Gerard Nijsten | M | - |
University of Amsterdam
| - |
Nina Sadowsky | F | - |
New York University
| - |
Anna Zaoui | F | - |
New York University
| - |
May Elaraby | F | - |
New York University
| - |
Thomas Kozak | M | - |
New York University
| - |
Thomas Richie | M | - |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | - |
Jui Cheng Ho | M | - |
New York University
| 4 ans |
Peter Min | M | - |
New York University
| - |
Amit Bansal | M | - |
New York University
| 5 ans |
Eric Kusseluk | M | 49 |
New York University
| 10 ans |
Anne M. Simonds | F | - |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | - |
G. J. M. van den Maagdenberg | M | 63 |
Academic Medical Center
Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | 10 ans |
Steven Cohen | M | 60 |
New York University
| - |
Andrea Bonime-Blanc | M | - |
New York University
| - |
Atzo Nicolaï | M | 64 |
University of Amsterdam
| - |
J. J. A. Leenaars | M | 72 |
University of Amsterdam
| - |
Jon A. Turner | M | 88 |
New York University
| - |
Ian Bremmer | M | - |
New York University
| - |
Jeffrey H. Lynford | M | 77 |
New York University
| - |
Solomon Steiner | M | 86 |
New York University
| - |
Steven H. Ferris | M | 80 |
New York University
| 51 ans |
Paul F. van der Heijden | M | 75 |
University of Amsterdam
| - |
Tony Kao | M | - |
New York University
| - |
Cornelius A. J. Herkströter | M | 87 |
University of Amsterdam
| - |
Clayton Rose | M | 65 |
New York University
| - |
John Paulson | M | 68 |
New York University
| - |
Steven R. Goldstein | M | 73 |
New York University
| 29 ans |
Lawrence Zicklin | M | 88 |
New York University
| - |
Andrea Campanini Bonomi | M | 59 |
New York University
| - |
Anthony Welters | M | 69 |
New York University
| - |
Paul H. Kramer | M | 71 |
New York University
| 41 ans |
Gary Cohn | M | 63 |
New York University
| - |
Christine Y. Homer | F | 57 |
New York University
| - |
Zachary W. Carter | M | 74 |
New York University
| - |
D. Edward I. Smyth | M | 74 |
New York University
| - |
Herbert I. London | M | 83 |
New York University
| 48 ans |
Murray Hidary | M | - |
New York University
| - |
Melvyn I. Weiss | M | - |
New York University
| - |
Harry Ballan | M | - |
New York University
| - |
Martin Edward Doerfler | M | - |
New York University
| - |
Nadine B. Hack | F | - |
New York University
| - |
Gary Warech | M | - |
New York University
| - |
Paul J. Massey | M | 64 |
New York University
| - |
Denise Gillen | F | - |
New York University
| - |
Marc Bell | M | 56 |
New York University
| - |
Hans Aerts | M | - |
University of Amsterdam
| - |
Frederick A. Bland | M | - |
New York University
| 34 ans |
Khaldoon Al-Mubarak | M | 48 |
New York University
| - |
Doug Lasdon | M | - |
New York University
| - |
Steven Perrick | M | 75 |
University of Amsterdam
| - |
Fraser P. Seitel | M | - |
New York University
| - |
Stephen N. Ifshin | M | 87 |
New York University
| - |
George David Smith | M | - |
New York University
| - |
Boris Jordan | M | 58 |
New York University
| - |
Randal Milch | M | 65 |
New York University
| - |
Lana Dubovik | F | - |
New York University
| 22 ans |
Anand Pandya | M | - |
New York University
| - |
Norman J. Marcus | M | - |
New York University
| - |
Leonard Wilf | M | - |
New York University
| - |
Leonard Hoogduin | M | 67 |
University of Amsterdam
| - |
Sjoerd E. Eisma | M | 75 |
University of Amsterdam
| - |
Amy Spellacy | F | - |
New York University
| - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Adri Baan | M | 82 |
Academic Medical Center
Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands.
University of Amsterdam
| - |
Emiel A. A. Roozen | M | 56 |
University of Amsterdam
| 5 ans |
Wim Henk Steenpoorte | M | 60 |
University of Amsterdam
| 6 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 78 | 78,00% |
Pays-Bas | 22 | 22,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jaap Goudsmit
- Réseau Personnel